Table 2.
Studies reporting hypothyroidism in patients receiving TKI therapy
| Reference | Tumor type | TKI used | Subjects with TFTs (n) |
Hypothyroidism (%) |
|---|---|---|---|---|
| (Desai et al. 2006) | GIST | sunitinib | 42 | 36% |
| (Rini et al. 2007) | RCC | sunitinib | 66 | 85% |
| (Schoeffski 2006) | RCC and GIST | sunitinib | 33 | 37% prospectively 57% retrospectively |
| (Wong et al. 2007) | GIST | sunitinib | 40 | 53% |
| (Martorella AJ 2006) | RCC | sunitinib | 39 | 20% |
| (Sabatier 2009) | RCC | sunitinib | 54 | 68% |
| (Shaheen 2006) | RCC | sunitinib | 55 | 73% |
| (Mannavola et al. 2007) | GIST | sunitinib | 24 | 46% |
| (Chu, et al. 2007) | GIST | sunitinib | 36 | 14% |
| (Wolter et al. 2008) | RCC and GIST | sunitinib | 59 | 27% |
| (Tamaskar, et al. 2008) | RCC | sorafenib | 39 | 18% |
| (de Groot et al. 2005) | GIST and MTC | imatinib | 11 | 73% |
| (de Groot, et al. 2007) | MTC | imatinib | 15 | 60% |
| (Sherman et al. 2008) | DTC | motesanib | 93 | 22% |
| (Dora et al. 2008) | CML | imatinib | 68 | 0% |